Editor, GPI 15715 or Aquavan injection (fospropofol disodium; MGI Pharma, Inc., Bloomington, Minnesota, USA) is a water-soluble, phosphono-O-methyl prodrug of propofol for intravenous (i.v.) injection. It has been evaluated for sedation during diagnostic and routine therapeutic procedures. The early evaluation studies were published mostly in Anesthesiology between 2003 and 2005. References 1 Fechner J, Ihmsen H, Hatterscheid D, et al. Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers. Anesthesiology 2003; 99:303-313. 2 Fechner J, Ihmsen H, Hatterscheid D, et al. Comparative pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 and propofol emulsion. Anesthesiology 2004; 101:626-639. 3 Struys MM, Vanluchene AL, Gibiansky E, et al. AQUAVAN, a water-soluble prodrug of propofol as a bolus injection: a phase I dose escalation comparison with DIPRIVAN. Part II: pharmacodynamics and safety. Anesthesiology 2005; 103:730-743. 4 Gibiansky E, Struys M, Gibiansky L, et al. AQUAVAN Injection, a watersoluble prodrug of propofol as bolus injection: a phase I dose escalation comparison with DIPRIVAN. Part 1: pharmacokinetics. Anesthesiology 2005; 103:718-729. 5 Schywalsky M, Ihmsen H, Tzabazis A, et al. Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. Eur J Anaesthesiol 2003; 20:182-190. 6 Fechner J, Ihmsen H, Schiessl C, et al. Sedation with GPI 15715, a watersoluble prodrug of propofol, using target-controlled infusion in volunteers.
Following i.v. administration, fospropofol is rapidly metabolized by alkaline phosphatase enzymes, releasing propofol FP . Several pharmacokinetic and pharmacodynamic studies have shown that propofol FP demonstrated differences in pharmacokinetic and pharmacodynamic profiles compared with propofol in a lipid solution [1] [2] [3] [4] [5] . We have recently discovered an assay problem that may have affected the measurement of propofol FP plasma concentrations in previously published studies. In the earlier studies [1] [2] [3] [4] 6] , blood samples were collected in tubes containing sodium orthovanadate (SOV; 60 mg added as a solid powder to maintain 10 mg ml À1 concentration) to prevent further in-vitro conversion of fospropofol to propofol by alkaline phosphatase enzymes. This was found to result in incomplete dissolution of the SOV powder and variable concentrations of SOV that affected plasma pH and caused haemolysis of many samples, leading to changes in propofol extraction recovery and storage stability. As a result, the propofol FP concentrations obtained in previous studies [1] [2] [3] [4] 6] could possibly be inconsistent and unreliable as the impact of the above-mentioned factors was neither known nor controlled, and, therefore, the originally reported propofol pharmacokinetic and pharmacodynamic results and the derived conclusions could be inaccurate. It was shown that the assay and stability problem was limited to quantitation of propofol FP and that it did not affect the fospropofol concentrations. The new drug application for fospropofol disodium was submitted to the Food and Drug Administration in September 2007. The propofol assay problem was reported in detail in the new drug application as well as details of revised assay methodology. Subsequent to the discovery of the problem, the sample-handling procedure was standardized to reduce variation in SOV concentration (e.g. SOV was as a solution) and improved sample handling and processing techniques that resolved the problems were developed and validated. Additional studies were then conducted using an appropriate assay to assess the pharmacokinetics and pharmacodynamics of fospropofol in healthy volunteers and patients. We plan to publish these results shortly, along with an estimate of the degree of error from the previously published studies that reported results using the old assay. We very much regret the magnitude of the originally published incorrect information and the confusion that it has and will cause in the pharmacokinetics of propofol from the use of fospropofol.
Reply, This letter led to discussions among the Editors-in-Chief of Anesthesiology, Anesthesia & Analgesia and the European Journal of Anaesthesiology regarding how to handle the previously published articles that used this assay. Our primary commitment is to our readers, including current and future investigators who are basing clinical practice and clinical investigation on these incorrect data. We have decided to publish correction statements regarding these articles indicating that the propofol concentration data are likely to be incorrect and that they should not be utilized. If we do not receive a manuscript that validates the new assay, analyses the likely error and bias in each of the six articles in question and determines how the error influences the conclusions within 12 months, we will retract these previously published articles. Drugs used for spinal anaesthesia in patients undergoing ambulatory knee arthroscopy: a survey of Dutch anaesthesiologists Editor, Lidocaine has been used for many spinal anaesthetics in ambulatory surgery since its introduction in 1948. Worldwide, lidocaine is used frequently for spinal anaesthesia, most of all because of its predictable onset and limited duration of action. Concerns about the use of lidocaine first arose in 1993 after the publication of some case reports about patients undergoing spinal anaesthesia [1] . Postoperatively, those patients experienced lower backache and pain in the buttocks and lower extremities. Subsequently, more case reports and studies about these symptoms, called transient neurological symptoms (TNS), have been published [2, 3] . Clearly, the incidence of TNS is higher after lidocaine spinal anaesthesia, one out of seven patients, than after other local anaesthetics [2] .
Local anaesthetics suitable for ambulatory surgery other than lidocaine have varying results and their toxicity is not always known [4] . Articaine is one of them [5] . It has the same short onset and short duration but its neurotoxicity has not yet been fully examined. Articaine is also not registered in The Netherlands for intrathecal use, although lidocaine is not registered for intrathecal use either. We believe that articaine is used by many anaesthesiologists in The Netherlands as an alternative to lidocaine.
To make an inventory of common practice in The Netherlands regarding drugs used for spinal anaesthesia in ambulatory surgery, we sent all 1089 anaesthesiologists a questionnaire. On the basis of an index case, all anaesthesiologists were asked which loco-regional technique, which local anaesthetic and which additive they would prefer for this case. Also, they were asked for the reasons why they would prefer this drug and technique. In the covering letter no remarks were made about the choice of technique or the use of particular local anaesthetics. The patient in this index case was a healthy 45-year-old man, height 185 cm and weight 80 kg. He was admitted for ambulatory knee arthroscopy.
Four hundred and sixty-two (42.4%) questionnaires were returned. Twenty out of the 462 were discarded because they were filled in incorrectly. Nineteen anaesthesiologists preferred a peripheral loco-regional blockade, resulting in 423 questionnaires being entered in the analysis of spinal, neuraxial anaesthesia.
Fifty per cent of the responders would choose lidocaine, 28% articaine, 13% bupivacaine, 5% prilocaine, 3% mepivacaine and 1% lidocaine with bupivacaine. Seven per cent would use additives such as fentanyl, sufentanil and clonidine. In general the dosage range for all chosen drugs was wide (Table 1) .
Lidocaine was chosen by 214 anaesthesiologists. Most of them (201) preferred a 2% plain concentration, but 1%, 1.5%, 2% heavy, 2.5%, 5% and 5% heavy were also mentioned.
Five per cent used additives such as fentanyl, sufentanil and clonidine. The short duration and quick onset were mentioned most frequently as the reasons for use. Articaine was chosen by 118 anaesthesiologists. The majority of this group (n ¼ 106) used a 5% concentration. Sixty said they preferred a 5% plain concentration, 46 anaesthesiologists used a 5% heavy concentration. Also, concentrations of 4%, 2% and even in one case a concentration of 10% were preferred. Only two anaesthesiologists in this group used additives.
Again the quick onset and short duration of action were mentioned. Beside these two reasons, the absence of TNS was mentioned by more than 25% of the anaesthesiologists in this group.
In this group, many different comments were made about the Dutch registration of articaine. Some anaesthesiologists said that this local anaesthetic is registered for spinal use. Others said that they regret the fact that articaine is not registered for this application.
Bupivacaine was used by 55 anaesthesiologists. Bupivacaine was given in only one concentration, 0.5% plain and heavy. Eighteen anaesthesiologists used additives such as fentanyl, sufentanil and clonidine. Remarks were made about the benefit of the longer duration of action in case the operation took longer or the advantage of starting some time before operation. Some anaesthesiologists mentioned that they did not want the neurological symptoms associated with the use of lidocaine, so instead they uses bupivacaine.
Prilocaine (n ¼ 21) and mepivacaine (n ¼ 11) were used by small groups. Prilocaine was the only local anaesthetic that was used without additives. Most of the anaesthesiologists in this group chose a 2% plain concentration (n ¼ 20) and one a 1.5% concentration. Dosage was between 40 and 80 mg. In particular, the lack of side effects such as TNS was mentioned by almost all 21 respondents.
Mepivacaine was used in varying concentration: plain 0.5%, 1.5%, 2%, 4% and 4% heavy. The dosage was widespread: between 45 and 160 mg. The reliability of the block and the absence of neurological problems were mentioned as motivations for usage.
Four anaesthesiologists preferred spinal anaesthesia with a combination of lidocaine and bupivacaine.
Lidocaine is used by the majority (50%) of the responding anaesthesiologists. Articaine is used by 28% of the responding anaesthesiologists. In addition to the time course of action, the incidence of transient neurologic symptoms is frequently mentioned as the reason for drug preference; however, articaine is not registered for intrathecal use in The Netherlands (correspondence from the Dutch registration authorities, CBG) or in Europe (www.emea.europa.eu). The lack of registered, properly investigated and documented alternatives for lidocaine may explain the ongoing high usage of lidocaine for this procedure despite a higher incidence of TNS in patients undergoing a knee arthroscopy, in particular [2] . The use of articaine as an alternative for lidocaine by Dutch anaesthesiologists may also lead to some concern regarding neurotoxicity. Although double-blind studies have confirmed that the efficacy of articaine in dentistry is comparable with lidocaine, some studies [6, 7] reported an increased incidence of paresthesias after the use of articaine. Our inventory of common practice in The Netherlands emphasizes the necessity of more research on the mechanisms of neurological dysfunction due to the application of local anaesthetics. Also, alternative drugs and combinations of drugs to replace lidocaine have to be thoroughly investigated and evaluated by registration authorities before their large-scale introduction into clinical practice.
with lower molecular weight and substitution that promote more rapid plasma clearance. As contrasted with HES 450/0.7, one such solution is HES 200/0.62; however, when compared with gelatin in randomized trials, HES 200/0.62 increased the incidence of acute renal failure (ARF) [2] and the need for renal replacement therapy (RRT) [3] .
Even lower substitution HES 200/0.5 was compared with modified Ringer's lactate in a recent multicentre randomized trial of 537 patients with severe sepsis or septic shock [4] . HES 200/0.5 increased the incidence of ARF, the recourse to RRT and, at higher doses, the frequency of death. Further confirmation has come from a new retrospective study of 563 patients who underwent coronary artery bypass graft or valvular surgery or both [5] . Exposure to HES 200/0.5 was an independent dose-dependent risk factor for acute kidney injury.
The hypothesis that reducing the molecular weight and substitution of HES still further might succeed in enhancing renal safety has been evaluated by Godet et al. [6] in a new multicentre randomized trial of 65 patients with preoperative renal dysfunction undergoing abdominal aortic surgery. HES 130/0.4 was compared with gelatin, and the primary renal safety endpoint was the peak increase in serum creatinine until the earlier of the sixth postoperative day or hospital discharge. Under the a-priori statistical analysis plan, HES 130/0.4 was to be judged no worse than gelatin as long as the one-sided 95% confidence limit for between-group difference in peak serum creatinine increase did not exceed 0.2 mg dl À1 ; however, that goal was not achieved in the trial. From the results of exploratory and nonparametric analyses, the investigators nevertheless argued in favour of noninferiority. In any case, this trial was not designed to assess ARF or RRT, and any firm conclusions about the renal safety of HES 130/0.4 must await adequately powered randomized trials focused on those endpoints.
One limitation of the trial by Godet et al. [6] , as well as some other trials discussed above, was reliance on gelatin as the comparator. According to extensive available evidence, including randomized trial data, artificial colloid itself exerts adverse effects on the kidney. Comparison with albumin as the control fluid might allow a more accurate appraisal of the renal safety of HES. In a new retrospective study of 44 patients with severe pulmonary failure, the need for RRT was examined during time periods before (1999-2001) and after (2002-2005) usage of albumin was curtailed, whereas the use of HES 130/0.4 was markedly increased [7] . Concurrent with the switch to HES 130/0.4, the proportion of patients requiring RRT increased from 5% to 64% (P < 0.01).
It now appears increasingly unlikely that modifications to molecular weight and substitution can solve the renal safety problems of HES. This emerging realization should perhaps be unsurprising, since the earliest report of HES-associated nephrotoxicity, appearing in 1991, concerned patients receiving low molecular weight and substitution HES 200/0.5 for haemodilution [8] .
Renal safety claims for the newest HES solutions have typically been based on small short-term trials evaluating endpoints other than ARF and RRT, frequently with other artificial colloids as the control fluid. More conclusive evidence is needed before such claims can be embraced.
References As it failed to relieve the spasm, however, nimodipine (2 mg) was additionally administered, which partially reversed the spasm in the ICA and right anterior cerebral artery segments. Selective catheterization of the middle cerebral artery did not succeed, as the microcatheter could not be negotiated. During these manoeuvres, the catheter guide buckled and was exchanged for a 6F guiding catheter. The ICA again went into severe spasm and nimodipine (2 mg) administration was repeated. Repeated injections led to hypotension, requiring inotropic support. Mechanical opening of the occlusion with a balloon was attempted without success. Stenting was considered but was ruled out as it could increase the risk of ICA dissection. As frequent manipulations exacerbated vasospasm, the procedure was abandoned and the patient was taken to the ICU. Entropy values remained persistently low at 20-25 despite maintaining similar anaesthetic depth. Mechanical ventilation was continued along with induced hypertension to optimize cerebral perfusion through collaterals. Immediate CT scan did not show evidence of ischaemia or haemorrhage. Antioedema measures and heparin were continued; however, the patient's neurological status failed to improve and repeat CT scan the following day showed a massive right ICA territory infarct, SAH and intraventricular haemorrhage. Her relatives refused consent for decompressive craniectomy, and she succumbed to her neurological insult 2 days later.
This article highlights the occurrence of two unusual yet significant events during the anaesthetic management of a neuroendovascular procedure, that is, acute reduction in entropy values and catheter-induced vasospasm of the ICA.
Spectral entropy is a monitoring modality designed to provide information on the state of the central nervous system during general anaesthesia. The entropy index is based on acquisition and processing of raw electroencephalogram and frontalis electromyogram signals [2] . Apart from providing information about the effect of anaesthetic agents on neuronal activity, it can also be influenced by changes in regional cerebral blood flow [3] .
The sudden drop in entropy values seen in our patient might have been due to various mechanisms that could have altered regional cerebral blood flow. We presume that this acute reduction in entropy could have been due to severe vasospasm from multiple manipulations in the ICA, which was already at risk from previous SAH. Secondly, trauma to the vessel with the catheter could have perforated the vessel wall causing leakage of blood and subsequent vasospasm; however, there was no demonstrable leak on angiogram in our patient. Finally, thromboembolism from the ICA during catheter manoeuvres is well known [4] . Repeated manipulations can denude vascular endothelium, exposing the vessel to thrombus formation.
Rooij et al. [4] found that procedural complications of coiling of intracranial aneurysm leading to permanent disability or death occurred in 5.9% of 681 patients. Ischaemic complications accounted for 80% and procedural rupture for 20% of complications. Thrombolytic agents were not used in our patient despite suspicion of thromboembolism for fear of aneurysmal rebleed; however, heparin was continued along with inotropes following the procedure after ruling out intracranial blood.
The outcome after iatrogenic complications during aneurysm coiling is poor; hence, early detection significantly enhances the chance of survival [5] . Entropy monitoring can alert the anaesthesiologist and radiologist of impending neurological damage so that action may be taken for the prompt restoration of adequate cerebral perfusion. Unnikrishnan et al. [6] have previously reported a sudden reduction in bispectral index during embolization of intracranial arteriovenous malformation due to ethanol-induced changes in intracranial dynamics.
The other unusual finding in our patient was severe spasm of the ICA. Such spasm during a neuroradiological procedure resulting in death is not described in the literature, although mechanically induced distal vasculature spasm is well documented [7] . It is angiographically difficult to differentiate a vasoocclusive phenomenon due to severe spasm from that of thromboembolism. Response to intraarterial dilators in our patient led us to believe that this complication was largely because of catheter-induced ICA spasm. Catheter-induced vascular injury from repeated endovascular manipulations results in flow disturbance and flow stagnation, exacerbating the preexisting parent vessel spasm caused by ruptured aneurysm [8] . In conclusion, our article illustrates a possible additional utility of entropy monitoring in detecting and predicting adverse intracranial events.
Editor, Epidural anaesthetic techniques continue to be the most effective and popular methods employed to provide analgesia for the parturient patient for labour and delivery. Patients with preeclampsia and eclampsia may present an increased risk of serious complications from neuraxial anaesthesia [1] . Alternative efficacious and safe analgesic methods would be useful adjuncts to obstetric anaesthesia, especially for this high-risk patient group.
Dexmedetomidine is a highly selective a 2 -adrenoreceptor agonist that, when administered as an intravenous infusion, possesses analgesic, sedative and haemodynamic controlling properties with minimal respiratory depression [2, 3] . The placental transfer is minimal and, therefore, little or no effect on the fetus should be seen. a 2 -Adrenoreceptor agonists have been shown to provide neuraxial analgesia via central a 2 -adrenoreceptors [4] and have been used successfully in the management of cancer pain [5] . Dexmedetomidine modulates the release of catecholamines and, therefore, may be useful when administered intravenously to patients with eclampsia in controlling the blood pressure [6] .
A 37-year-old pregnant woman was admitted for induction of labour because of the development of mild-tomoderate preeclampsia. She was at 38 weeks' gestation and gravida 5 para 3 þ 1 with a single cephalic presentation pregnancy. Her blood pressure was 150/90 mmHg at admission, and she had 3þ proteinuria. She had a history of insulin-dependent diabetes and a random blood sugar level of 198 mg dl À1 .
There was no history of recent headache, visual disturbances or preseizure activity. She was 1.6 m tall and weighed 98 kg. There was no lower limb oedema. Shortly after admission to the obstetric unit, her blood pressure was 170/105 mmHg, and she still had 3þ proteinuria. Her vaginal examination revealed that the Bishop score was less than 3; so induction of labour was initiated with the insertion of a prostaglandin E 2 vaginal tablet. Three hours later the patient started to have regular uterine contractions every 3-5 min, each lasting for 35 s. She had 2 cm cervical dilatation with 60% effacement and a nonengaged fetal head. Her pain during uterine contractions was increasing in intensity with a visual analogue scale (VAS) score of 6-7.
Laboratory data included a haemoglobin concentration of 11.8 g dl À1 (normal range: 12-16 g dl À1 ), platelet count 183 000 l À1 (normal range: 140 000-440 000 l À1 ), prothrombin time 14.1 s (normal range: 11.5-15.5 s), activated prothombin time 34.1 s (normal 27-35 s), normal liver enzymes and normal renal function tests. Total serum protein was 6.6 g dl À1 (normal range: 6-8 g dl À1 ) and serum albumin of 3.3 g dl À1 (normal range: 3.5-5 g dl À1 ). A magnesium sulphate intravenous infusion was started as prophylaxis against the development of eclampsia.
Epidural analgesia was offered as an option for labour pain relief but was declined by the patient. The intravenous infusion of dexmedetomidine was discussed with the patient. After written informed consent and approval by our ethics committee was obtained, this 'off-label' use of the drug was commenced. A bolus dose of dexmedetomidine was not given. The infusion was started with a low dose of 0.2 mg kg À1 h À1 . Dexmedetomidine was diluted (200 mg in 48 ml of normal saline) and infused via an infusion syringe pump. The patient's pain was monitored using the VAS, and the dexmedetomidine infusion was increased by 0.1 mg kg À1 h À1 every 30 min to a maximum of 0.5 mg kg À1 h À1 to reduce the VAS score to a range of 0-3. Sedation was monitored with the Ramsay Sedation Score (RSS) and the patient was maintained with an RSS of 2-3 by adjusting the dexmedetomidine infusion rate [7] .
An oxytocin infusion was administered to accelerate the course of labour. During labour, blood pressure remained elevated with a diastolic pressure around 100 mmHg despite an infusion of dexmedetomidine of 0.4 mg kg À1 h À1 . The VAS score was well controlled with scores of 3, 3, 2, and 2 at 30, 60, 120 and 180 min, respectively. The RSS was well maintained at 2, and the arterial oxygen saturation (SpO2), respiratory rate and pulse rate were maintained in the normal range ( Fig. 1) . After 3 h of the dexmedetomidine infusion it was decided to undertake a Caesarean section because of the presence of persistent late decelerations in fetal heart rate. This was performed under general anaesthesia. A lively 3.7 kg female infant was delivered successfully with an Apgar score of 8-9. The infant was admitted to the neonatal intensive care unit as a precaution because the mother was a diabetic patient. After delivery, the mother and the baby did well and were discharged home in excellent condition after 7 days.
When a labour epidural is contraindicated or declined by the patient, the alternatives include natural childbirth techniques [8] or opioid-based techniques [9] . However, both techniques may be associated with poor analgesia and the opioid technique with maternal and fetal respiratory depression. Although dexmedetomidine has not been approved for intravenous use during pregnancy, it is reported to have been used in pregnant patients undergoing nonobstetric surgery [10] . Dexmedetomidine was shown to decrease the total dose of opioids, promote haemodynamic stability and maintain maternal homeostasis and uteroplacental blood flow. In-vitro studies on human placentas have demonstrated a low maternalfetal transfer of dexmedetomidine, presumably because of its high lipophilicity [11] . These characteristics of dexmedetomidine may make it an ideal intravenous analgesic for labour when an epidural technique is contraindicated. There were no incidences of maternal bradycardia or hypotension. In this case, there was fetal heart rate deceleration associated with uterine contraction, but the underlying fetal heart rate was normal. The potential specific advantages of dexmedetomidine in patients with preeclampsia with its specific action for blood pressure control potentially offer a very significant advantage over current techniques. A pilot study is indicated to explore the role of dexmedetomidine administered intravenously in this high-risk parturient group. Editor, Is our world really just as it appears to be, and, viewing it pragmatically, is this all that counts? Or, do we need to know more about its hidden but nevertheless essential nature? The behaviourists tried, at the beginning of the 20th century, to dismiss the underplaying mechanisms of behaviour in an attempt to arrive at effective therapy. Indeed, that therapy remained one of the most successful, though the underlying philosophy lost its original vigour. In clinical medicine we have a quasi-parallel that is called the 'intention-to-treat' principle: the mechanisms of therapeutic measures are less important and what counts is whether the given therapy (that, in principle, works) can be implemented or not. Unfortunately, sometimes such studies may ignore valuable information that is, in principle, at hand. A recent clinical trial by Avidan et al. [1] illustrates the problem quite well. One of the methods for monitoring the depth of anaesthesia is by monitoring either alveolar concentration of general anaesthetic gas [fraction of minimal alveolar concentration (MAC)] or brain electrical activity of the patient, as expressed by the bispectral analysis (BIS). It is claimed that BIS could be useful to avoid accidental awareness of the patient and may be better than just MAC monitoring. Still, doubts persist. The aforementioned recent large study [1] demonstrated that perioperative awareness is an extremely rare event (0.2%). We have two points to make about this recent study that will illustrate two very general research problems.
Sometimes our methods may hide the event under investigation. In theory, if patients are in superficial narcosis during an operation, we could, by measuring their brain activity, detect the moments when they are not sleeping deep enough and could hear what is going on around them and could later recall some parts of the conversation in the operating theatre. But if patients are in deep narcosis (i.e. deep sleep), they would not recall anything that happened perioperatively. In principle (yet to be proven), we can monitor the brain activity and finely tune the depth of the narcosis; however, if we induce very deep narcosis, our monitoring of the brain activity would be useless, as the patient will have no awareness episodes anyway. This was apparently the case in the cited study; therefore, usefulness of BIS monitoring could not have been examined in this trial. The results of that study did not answer the question that was asked, not because the event that was examined was not there but because we, by using a false method, made it invisible.
The second point concerns the 'intention-to-treat' analysis [2] mentioned above. In a clinical trial, when examining the results of one intervention, if data analysed are the only data obtained after strict application of the protocols, the analysis is called analysis 'per protocol'. This means comparing the results after discarding all errors, dropouts or changes in the experimental protocol;
put simply, when applying the rules that are set before the study. In an ideal case, we will then have only one variable and could infer something about the mechanisms of the intervention that were taking place. On the contrary, we can perform, at the same time, the analysis according to how the study was planned a priori, an 'intention-to-treat' analysis, including all the patients as they were assigned at the beginning, no matter what happened to them during the study (changed treatment, dropped out, etc., which would in fact include more variables). The results of such an analysis would not tell us much about the mechanisms of the intervention that we are examining because, if the other factors (other variables) are too important, such as therapy change or dropout rate, the results would reflect more their effects and less the effects of the intervention under examination. For example, a very good but expensive drug may be examined and could be demonstrated that 'it does not work' in a third world country because, being too expensive, it is seldom given.
Indeed, the first analysis would tell us something about the mechanisms involved only if it were correctly conducted and if not too many violations of the protocol happened. The second analysis would tell us something about the practical feasibility of the given intervention that was under examination. The first speaks about the cause and effect relation of the intervention and its effects. The second about how our world in that respect is. Indeed, the cause-effect relation may be invisible, but if we would ignore it completely, we would not be much closer to the secrets of nature than the primitive men who knew that the Sun would rise every morning but ignored the fact that it was our Earth which in fact had been turning its face toward the Sun and not the opposite.
The cited study demonstrated the first point very clearly: the awareness was such a rare event that the study could not answer the question asked, that is, can BIS be used to detect awareness? There was almost no awareness that could be examined. In addition, by applying the analysis 'intention-to-treat' only, and depriving the reader of the description of all necessary conditions of the trial, it was impossible to analyse the mechanisms of awareness and see why some patients reported awareness, or why almost nobody reported awareness. Therefore, similar to the previous studies [3, 4] , this study also contains fatal methodological errors.
A reader could then, after accepting the study results, be free to draw unwarranted conclusions. It could, for example, be inferred that, if the anaesthesiologists are conscious that they are taking part in a study and if the levels of MAC or BIS are set as they were, the awareness would be reduced to the 'very rare event'. As a result, not only would the 'theoretical' mechanisms of the accidental awareness during general anaesthesia be almost inaccessible for the cause-effect analysis, but also they would then be irrelevant! Or, one could conclude that the absence of awareness is assured if an anaesthesiologist would just do her/his job correctly! If such 'intention-totreat' study designs, while pursuing pragmatic aims, were to prevent us from rational thinking about the mechanisms of these events, would we not then be running the risk of missing the opportunity to get more out of the hidden nature of our world? As we know so well, nature does not reveal its secrets spontaneously; this time, no wonder, it has remained silent. We are obviously still in need of one well controlled study based on a solid methodology.
Editor, A 67-year-old woman presented for left breast needle localized excision biopsy. Her hypertension was controlled by diltiazem, bendrofluazide, and irbesartan. She had had restless legs syndrome (RLS) since the age of 13 and took pramipexole (a dopamine agonist) 125 mg once daily for this, usually in the late afternoon, when her symptoms were worst. She was not aware of any anaesthetic problems previously. Preoperatively, she had self-administered her antihypertensive medication, but not her pramipexole because she was symptom free.
After placement of standard monitoring equipment, a 20G cannula was inserted into the dorsum of her right hand. Immediately after preinduction, her blood pressure (BP) was 160/90 mmHg. After preoxygenation, anaesthesia was induced with 75 mg fentanyl and 240 mg propofol. A size-4 disposable laryngeal mask airway was inserted, and spontaneous respiration continued throughout the anaesthetic, which was maintained using sevoflurane in an air/oxygen mixture (FiO 2 0.6). One litre of Hartmann's solution and 50 mg cyclizine was administered intravenously. Five minutes after skin incision, her BP increased to 180/100 mmHg. She received a further 25 mg fentanyl, 1 g of paracetamol and 75 mg diclofenac sodium intravenously, and the monitored minimum alveolar concentration of sevoflurane was increased from 1.1 to 1.3. Her BP remained between 160/90 and 190/100 mmHg for the duration of the half-hour procedure. Her heart rate was 75-85 beats min À1 and her respiratory rate was 19-24 beats min À1 . The wound was infiltrated with 20 ml of 0.5% bupivacaine after skin closure. On rapid emergence from anaesthesia, she was very agitated, complaining of pain in her legs relieved slightly by vigorous movement. She was administered 30 mg dihydrocodeine orally and 125 mg of oral pramipexole. Thirty minutes later, she reported good relief from her leg pains and her BP gradually settled to 120/60 mmHg.
RLS affects 7-10% of adults (0.5-1% children) of mainly European origin, with increased prevalence among women and patients aged 60-70 years. The condition is underrecognized in the surgical population. Aetiologically, genetic and environmental factors are implicated: familial inheritance is seen, but a specific gene has not been found and specific causation remains uncertain [1] . RLS may be a primary condition, or be secondary to iron deficiency, renal failure, pregnancy, or the use of certain medications (dopamine antagonists, neuroleptics, selective serotonin reuptake inhibitor and tricyclic antidepressants, antihistamines, caffeine, alcohol, nicotine) [2] . The diagnosis is clinical, requiring an urge to move the legs (and less commonly other parts of the body) usually accompanied by an uncomfortable sensation, occurrence at rest, improvement with activity, and worsening of symptoms in the evening or at night. RLS has disruptive effects on sleep quality and daily life. Treatment of secondary causes of RLS may result in improvement or resolution of symptoms. Approximately one-third of patients require medication for symptomatic relief. Dopamine agonists (pramipexole, ropinirole, rotigotine), anticonvulsants (gabapentin), benzodiazepines (clonazepam, temazepam), and opioids (codeine, tramadol) may be beneficial.
Patients with RLS should be scheduled for morning operating lists. Preoperatively, they should be encouraged to take their usual RLS medication. Premedication with benzodiazepines and opioids should be considered. Certain drugs can exacerbate the condition and should be avoided perioperatively, including butyrophenones (haloperidol, droperidol), sedative anihistamines (cyclizine -the likely cause of exacerbation in out patient), dopamine antagonist antiemetics (metoclopramide, prochlorperazine), and opioid antagonists (naloxone). 5-HT3 receptor antagonists should be used for antiemesis. Ketamine may be preferred for the induction of anaesthesia [3] . Involuntary leg movements may persist after the administration of spinal or epidural anaesthesia, but may be minimized by the addition of opioids to intrathecal or (continuous) epidural local anaesthesia. Anecdotally, intravenous magnesium [4] and physostigmine [5] have provided symptomatic control. The use of graduated compression stockings and calf compressors may also be beneficial [6] . Postoperatively, patients should be encouraged and assisted to mobilize early, and adequate (opioid) analgesia should be given, as immobility and pain can exacerbate symptoms [7] . Iron supplementation should be considered perioperatively, particularly when operative blood loss is likely to be significant.
impression that it was correctly filled [2] , but we are uncertain whether this might have occurred in our case. Also, it has previously been noted that the Isotec 5 fill level may rise over a 10 min period when left to stand [1] , such that checking the sight glass immediately after topping up the vaporizer would not reveal overfilling. We note also that, because of the design of the sight glass on this model, the liquid level in an overfilled vaporizer is visible only to an anaesthetist or assistant in the sitting position in front of the machine or stooping to inspect it.
